Availability of Ozempic®

HPS Pharmacies wish to advise that Novo Nordisk has released a new presentation of Ozempic^®, as follows:

Ozempic^® 0.25/0.5mg Pen
Semaglutide 0.68 mg/mL, 3 mL
ARTG 446290

This new product replaces the Ozempic^® 0.25/0.5mg 1.5 mL pen (Semaglutide 1.34mg/mL, ARTG 308324). The 1.5 mL pen will be discontinued in December 2025.

The new 3 mL Ozempic^® 0.25 mg/0.5 mg pen and the older 1.5 mL Ozempic^® 0.25 mg/0.5 mg pen are considered interchangeable from a bioequivalence perspective. They each deliver the same dose of active ingredient, contain the same number of doses, and have the same administration instructions. However, they are currently not ‘a-flagged’ on the Pharmaceutical Benefits Scheme (PBS).

Please click here for further information around prescribing and supplying Ozempic^® on the PBS.

While Novo Nordisk continues to increase manufacturing capacity, all Ozempic^® products are expected to have limited availability throughout 2025. Internationally registered alternatives have been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please be aware that additional delivery lead times may apply to Section S19A products.

For more information on availability, please go to the Ozempic (semaglutide) shortage page on the TGA website.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.

Download PDF